Among patients with KRAS WT tumors, Bengala et al. reported a trend toward a greater rate of tumor regression (36.7% for KRAS WT versus 11% for KRAS mutant), however it did not reach statistical significance (P = .12) [101]. The gene discussed is KRAS; the disease is neoplasm.